Berinert Package Insert

SPECIALTY GUIDELINE MANAGEMENT
BERINERT (C1 esterase inhibitor [human]) POLICY . Berinert [package insert]. Kankakee, IL: CSL Behring LLC; February 2015. 2. Micromedex Solutions [database online]. Ann Arbor, MI: Truven Health Analytics Inc. Updated periodically. ... Fetch Content

HIGHLIGHTS OF PRESCRIBING INFORMATION RUCONEST RUCONEST.
Each package contains one single-use vial of RUCONEST. To reconstitute, the following are also required: • Sterile Water for Injection (diluent) - At least 14 mL per vial of RUCONEST requiring ... Access Document

FORMULARY EXCEPTIONS CRITERIA - Providers.bcidaho.com
Targeted • Berinert(C1 esterase inhibitor [human]) II. EXCEPTION CRITERIA . Coverage for the targeted product is provided when any of the following criteria is met: Ruconest [package insert]. Raleigh, NC: Santarus, Inc.; February 2015. Author: ... Document Viewer

Thrombosis Factor IX Complex Profilnine Surgery, Post Surgery ...
Surgery, post surgery, with known liver disease, and with signs of fibrinolysis, thrombosis, or DESCRIPTION Open the Mix2Vial® package by peeling away the lid (Figure 1). Leave the Mix2Vial in the clear outer packaging. 5. ... Read More

KAISER PERMANENTE - PORTLAND MEDICATION REQUEST GUIDELINES C1 ...
KAISER PERMANENTE - PORTLAND MEDICATION REQUEST GUIDELINES C1 ESTERASE INHIBITOR. Generic Brand HICL GCN Exception/Other C1 ESTERASE INHIBITOR BERINERT, Berinert package insert. Kankakee, IL. July 2012. • ViroPharma, Inc. Cinryze product information. Exton, PA. ... Fetch Content

Last Review Status/Date - Media.fepblue.org
Berinert while maintaining optimal therapeutic outcomes. References 1. Berinert [package insert]. Kankakee, IL: CSL Behring LLC.; September 2017. Policy History Date Action June 2011 New Policy January 2012 FDA approved new indication of treatment of acute laryngeal attacks of ... Read Here

Reconstitution Of Berinert®1 - Seqirus.com.au
See package insert or Full Product Information. Reconstitution of Berinert®1 Mix2Vial™ instructions FLIP Water STEP 1 STEP 2 STEP 3 INCORRECT CONNECTION METHODS STEP 4 STEP 5 STEP 6 Place Water vial on a level surface and hold firmly Pierce the Water vial with the Mix2Vial set Pull out the outer package and invert Water vial ... Get Document

UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program ...
Berinert is a plasma-derived C1 esterase inhibitor (human) indicated for the treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) in adult Berinert [package insert]. Kankakee, IL: CSL Behring LLC; September 2017. ... Return Doc

Helixate 1-22-10 Rev 2 - BDI Pharma
Helixate®FS 10. STABILITY AND REACTIVITY Stability Stable for period indicated on the label when stored at conditions specified in product package insert. Incompatibility No known incompatibilities. Hazardous Decomposition Products No known hazardous decomposition products. Hazardous Polymerization Hazardous polymerization will not occur. ... Access Full Source

Berinert, Cinryze - Member.carefirst.com
Berinert, Cinryze. Prior Authorization Request . Cinryze, skip to Clinical Criteria Questions Berinert. B. The preferred product for your patient's health plan is Ruconest. Can the patient’s treatment be package insert, AHFS, Lexicomp, Clinical Pharmacology, Micromedex, current ... Access Content

C1 Esterase Inhibitor (human) - UW Blogs Network
C1 esterase inhibitor (human) For the prevention and treatment of acute attacks of Hereditary Angioedema. Reid Nakagawa. November 31, 2013. OUtline. Hereditary Angioedema. Definition. Epidemiology. Berinert [package insert]. Kankakee, IL: CSL Behring LLC; 2012. ... Return Doc

Pharmacy Policy Bulletin - AmeriHealth
Pharmacy Policy Bulletin Title: Hereditary Angioedema Agents Policy #: C1 esterase inhibitor (human) Berinert is approved for the treatment of acute abdominal, facial, or laryngeal attacks of HAE in adults and adolescents with recommendation by an Firazyr (icatibant) [package insert ... Retrieve Doc

PHARMACY POLICY STATEMENT - CareSource
Medication is not being used in combination with Berinert, Firazyr, or Kalbitor; AND 6. Medications known to cause angioedema (i.e. ACE-Inhibitors, estrogens, angiotensin II receptor blockers) have been evaluated and discontinued when appropriate. 7. Dosage allowed: weight based dosing per package insert; do not exceed 4200 IU per dose and no ... Fetch Full Source

Berinert - Prior Authorization Criteria (Non HCUSA ...
1. ®Berinert [package insert]. Kankakee, IL: CSL Behring; February 2015. 2. Bowen T, Cicardi M, Bork K, et al. Hereditary angioedema: a current state-of-the-art review, VII: Canadian Hungarian 2007 international consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. ... Read Here

Berinert® (C1 Esterase Inhibitor, Human) - EmblemHealth
Berinert [package insert]. Kankakee, IL; CSL Behring LLC; September 2017. Accessed January 2018. 2. Bygum A, Andersen KE, Mikkelsen CS. Self-administration of intravenous C1-inhibitor therapy for hereditary angioedema and associated quality of life benefits. Eur J Dermatol. ... View Document

Optimizing Screening And Management Of The Patient With ...
Optimizing Screening and Management of the Patient with Hereditary Angioedema: Berinert® [C1 Esterase Inhibitor (Human)] [package insert]. Kankakee, IL; CSl Behring Human C1-esterase inhibitor concentrate (Berinert). BioDrugs. 2009;23(6):399-406. 19. Cicardi M, Levy R, McNeil D, et al ... Return Doc

This Pdf Is An Accompaniment To This Educational Activity ...
(Berinert ®) • Recombinant human C1-INH Firazyr [package insert]. Lexington, MA: Shire; 2015. Comparison of Acute HAE Therapies • Does the patient require long-term prophylaxis? – Not all HAE patients – Need varies by individual • Frequency, severity, and type of attacks ... Get Doc

Cinryze, INN-C1 Inhibitor (human) - Ema.europa.eu
Cinryze Asessment report Page 6/64 During the CHMP meeting on 15-18 November 2010, the CHMP agreed on a list of outstanding issues to be addressed in writing and/or in an oral explanation by the applicant. ... Fetch Here